New drug cocktail aims to stop myeloma in its tracks
NCT ID NCT07297329
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial is testing whether adding an experimental drug called SCTC21C to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) can help people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The study will enroll 292 participants and measure how long the cancer stays under control and whether cancer cells become undetectable. The goal is to improve outcomes without requiring lifelong treatment, though ongoing monitoring will still be needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SCTC21C (an experimental drug given as an infusion under the skin) combined with bortezomib, lenalidomide, and dexamethasone
What this could lead to
If successful, this combination could help control multiple myeloma longer and increase the chance of eliminating all detectable cancer cells.
What could go wrong
This is an early-phase trial with 292 participants, so results may not apply to everyone. Adding SCTC21C could also increase side effects like infections or organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Chaoyang Hospital affiliated to Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••